132 related articles for article (PubMed ID: 38841819)
1. Addition of quantitative MRI to the routine clinical care of patients with multiple sclerosis-Results from the MAGNON project.
Leussink VI; Jankovic M; Groth M; Schuh K; Sauerbeck IS; Hoffmann O
Brain Behav; 2024 Jun; 14(6):e3548. PubMed ID: 38841819
[TBL] [Abstract][Full Text] [Related]
2. A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: Physicians' and patients' views.
Ziemssen T; Tolley C; Bennett B; Kilgariff S; Jones E; Pike J; Tomic D; Piani-Meier D; Lahoz R
Mult Scler Relat Disord; 2020 Feb; 38():101861. PubMed ID: 31865132
[TBL] [Abstract][Full Text] [Related]
3. Thalamic asymmetry in Multiple Sclerosis.
Ramezani N; Davanian F; Naghavi S; Riahi R; Zandieh G; Danesh-Mobarhan S; Ashtari F; Shaygannejad V; Sanayei M; Adibi I
Mult Scler Relat Disord; 2023 Sep; 77():104853. PubMed ID: 37473593
[TBL] [Abstract][Full Text] [Related]
4. Composite Marker of Cognitive Dysfunction and Brain Atrophy is Highly Accurate in Discriminating Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis.
Kizlaitienė R; Kaubrys G; Giedraitienė N; Ramanauskas N; Dementavičienė J
Med Sci Monit; 2017 Feb; 23():588-597. PubMed ID: 28145395
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF
Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299
[TBL] [Abstract][Full Text] [Related]
6. Continuous diffuse brain atrophy independent of relapse as a hallmark of multiple sclerosis beginning from relapsing-remitting stage.
Akaishi T; Fujimori J; Yokote H; Nakashima I
Clin Neurol Neurosurg; 2024 Jul; 242():108342. PubMed ID: 38772279
[TBL] [Abstract][Full Text] [Related]
7. Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS.
Rocca MA; Valsasina P; Meani A; Gobbi C; Zecca C; Rovira À; Montalban X; Kearney H; Ciccarelli O; Matthews L; Palace J; Gallo A; Bisecco A; Gass A; Eisele P; Lukas C; Bellenberg B; Barkhof F; Vrenken H; Preziosa P; Comi G; Filippi M;
Neurology; 2019 Nov; 93(20):e1852-e1866. PubMed ID: 31611336
[TBL] [Abstract][Full Text] [Related]
8. Multiple sclerosis by phenotype in Germany.
Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
[TBL] [Abstract][Full Text] [Related]
9. Results from SPECTRUM: A survey of healthcare professionals to understand current diagnosis and management practices for secondary progressive multiple sclerosis in the United Kingdom.
Duddy M; Wilkinson C; Medhurst S; Rhys K
Mult Scler Relat Disord; 2021 Oct; 55():103174. PubMed ID: 34399317
[TBL] [Abstract][Full Text] [Related]
10. Identification and diagnosis of Secondary Progressive Multiple Sclerosis during the clinical encounter: Results from a physician survey.
Alvarez E; Nair KV; Gorritz M; Bartolome L; Maloney H; Ding Y; Golan T; Wade RL; Kumar R; Su W; Shah R; Russo P
Mult Scler Relat Disord; 2021 May; 50():102858. PubMed ID: 33799068
[TBL] [Abstract][Full Text] [Related]
11. Central nervous system atrophy predicts future dynamics of disability progression in a real-world multiple sclerosis cohort.
Tsagkas C; Naegelin Y; Amann M; Papadopoulou A; Barro C; Chakravarty MM; Gaetano L; Wuerfel J; Kappos L; Kuhle J; Granziera C; Sprenger T; Magon S; Parmar K
Eur J Neurol; 2021 Dec; 28(12):4153-4166. PubMed ID: 34487400
[TBL] [Abstract][Full Text] [Related]
12. [A current view on the MRI diagnosis of multiple sclerosis: an update of 2016 revised MRI criteria].
Bryukhov VV; Krotenkova IA; Morozova SN; Krotenkova MV
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(2. Vyp. 2):66-73. PubMed ID: 28617364
[TBL] [Abstract][Full Text] [Related]
13. A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study.
Ziemssen T; Piani-Meier D; Bennett B; Johnson C; Tinsley K; Trigg A; Hach T; Dahlke F; Tomic D; Tolley C; Freedman MS
J Med Internet Res; 2020 Feb; 22(2):e16932. PubMed ID: 32049062
[TBL] [Abstract][Full Text] [Related]
14. Functional Disability and Brain MRI Volumetry Results among Multiple Sclerosis Patients during 5-Year Follow-Up.
Strautmane S; Balodis A; Teivane A; Grabovska D; Naudins E; Urbanovics D; Fisermans E; Mednieks J; Flintere-Flinte A; Priede Z; Millers A; Zolovs M
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374286
[No Abstract] [Full Text] [Related]
15. Differentiation of relapsing-remitting and secondary progressive multiple sclerosis: a magnetic resonance spectroscopy study based on machine learning.
EkŞİ Z; ÇakiroĞlu M; Öz C; AralaŞmak A; Karadelİ HH; Özcan ME
Arq Neuropsiquiatr; 2020 Dec; 78(12):789-796. PubMed ID: 33331515
[TBL] [Abstract][Full Text] [Related]
16. Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.
Boyko A; Therapontos C; Horakova D; Szilasiová J; Kalniņa J; Kolontareva J; Gross-Paju K; Selmaj K; Sereike I; Milo R; Gabelić T; Rot U
Mult Scler Relat Disord; 2021 May; 50():102778. PubMed ID: 33592384
[TBL] [Abstract][Full Text] [Related]
17. [Neuropsychological and MRI diagnostics in secondary progressive multiple sclerosis].
Penner IK; Gass A; Schreiber H; Wattjes MP
Nervenarzt; 2021 Dec; 92(12):1293-1301. PubMed ID: 33891150
[TBL] [Abstract][Full Text] [Related]
18. Personalized maps of T1 relaxometry abnormalities provide correlates of disability in multiple sclerosis patients.
Chen X; Schädelin S; Lu PJ; Ocampo-Pineda M; Weigel M; Barakovic M; Ruberte E; Cagol A; Marechal B; Kober T; Kuhle J; Kappos L; Melie-Garcia L; Granziera C
Neuroimage Clin; 2023; 37():103349. PubMed ID: 36801600
[TBL] [Abstract][Full Text] [Related]
19. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
20. Cervical cord area is associated with infratentorial grey and white matter volume predominantly in relapsing-remitting multiple sclerosis: A study using semi-automated cord volumetry and voxel-based morphometry.
Bellenberg B; Schneider R; Weiler F; Suchan B; Haghikia A; Hoffjan S; Gold R; Köster O; Lukas C
Mult Scler Relat Disord; 2015 May; 4(3):264-72. PubMed ID: 26008944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
